Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Pervasive glycative stress links metabolic imbalance and muscle atrophy in early-onset Parkinson's disease
Show others and affiliations
Number of Authors: 282025 (English)In: Molecular Metabolism, ISSN 2212-8778, Vol. 97, article id 102163Article in journal (Refereed) Published
Abstract [en]

Objective: Parkinson’s disease (PD) is recognized as a systemic condition, with clinical features potentially modifiable by dietary intervention. Diets high in saturated fats and refined sugars significantly increase PD risk and exacerbate motor and non-motor symptoms, yet precise metabolic mechanisms are unclear. Our objective here was to investigate the interplay between diet and PD-associated phenotypes from a metabolic perspective.

Methods: We explored PARK7 KO mice under chronic glycative stress induced by prolonged high-fat high-sucrose (HFHS) diet. We investigated metabolic consequences by combining classical metabolic phenotyping (body composition, glucose tolerance, indirect calorimetry, functional assays of isolated mitochondria) with metabolomics profiling of biospecimens from mice and PD patients.

Results: We found this obesogenic diet drives loss of fat and muscle mass in early-onset PD mice, with a selective vulnerability of glycolytic myofibers. We show that PD mice and early-onset familial PD patients are under pervasive glycative stress with pathological accumulation of advanced glycation end products (AGEs), including N-α-glycerinylarginine (α-GR) and N-α-glycerinyllysine (α-GK), two previously unknown glycerinyl-AGE markers.

Conclusions: Our results offer the first proof for a direct link between diet, accumulation of AGEs and genetics of PD. We also expand the repertoire of clinically-relevant glycative stress biomarkers to potentially define at-risk patients before neurological or metabolic symptoms arise, and/or to monitor disease onset, progression, and effects of interventions.

Place, publisher, year, edition, pages
2025. Vol. 97, article id 102163
Keywords [en]
Advanced glycation endproducts (AGEs), Biomarkers, Glycative stress, Glycobiology, Muscle atrophy, Parkinson's disease
National Category
Neurology
Identifiers
URN: urn:nbn:se:su:diva-245021DOI: 10.1016/j.molmet.2025.102163ISI: 001498383100001PubMedID: 40345387Scopus ID: 2-s2.0-105005470061OAI: oai:DiVA.org:su-245021DiVA, id: diva2:1997348
Available from: 2025-09-12 Created: 2025-09-12 Last updated: 2025-09-12Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Keipert, SusanneJastroch, Martin

Search in DiVA

By author/editor
Keipert, SusanneJastroch, Martin
By organisation
Department of Molecular Biosciences, The Wenner-Gren Institute
In the same journal
Molecular Metabolism
Neurology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 10 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf